• Wesam A Mokhtar, Laila M Sherief, Naglaa M Kamal, Azza O ElSheikh, Farida H Omran, Ahmed Abdulsaboor, Maha M H Sakr, Shreif El Gebally, Mohamed M M Shehab, Jaber Alfaifi, Reem Turkistani, Futun Aljuaid, Mohammed A M Oshi, Fouad B A Elbekoushi, and Ghada A Mokhtar.
• Pediatric Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
• Medicine (Baltimore). 2024 Mar 8; 103 (10): e37356e37356.

AbstractPlasma gelsolin (pGSN) correlates with clinical improvement in septic patients. We aimed to investigate pGSN levels as a diagnostic and prognostic marker of neonatal late-onset-sepsis (LOS). A case-control study was done on 184 neonates (92 with LOS and 92 controls). All participants were subjected to detailed history taking, full clinical evaluation, sepsis workup, and pGSN enzyme-linked immunosorbent-assay measurement. We detected significantly lower pGSN level among cases compared to controls (90.63 ± 20.64 vs 451.83 ± 209.59). It was significantly related to the severity of sepsis and mortality, with significantly lower values among cases with septic shock and multiorgan failure and non-survivors. Follow-up pGSN significantly increased after sepsis improvement in survivors compared to admission values. pGSN might be a reliable diagnostic and prognostic marker for LOS.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

10 keywords...

hide…